TY - JOUR
T1 - Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention
T2 - A model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey
AU - Davies, A.
AU - Bakhai, A.
AU - Schmitt, C.
AU - Barrett, A.
AU - Graham-Clarke, P.
AU - Sculpher, M.
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Objective: To evaluate the long-term cost-effectiveness of 12-months treatment with prasugrel vs clopidogrel from four European healthcare systems' perspectives (Germany, Sweden, the Netherlands, and Turkey). Methods: In the TRITON-TIMI 38 trial, patients with an acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) were treated with prasugrel or clopidogrel. Prasugrel reduced the composite end-point (cardiovascular death, MI, or stroke), but increased TIMI major bleeding. A Markov model was constructed to facilitate a lifetime horizon for the analysis. A series of risk equations constructed using individual patient data from TRITON-TIMI 38 was used to estimate risks of clinical events. Quality-adjusted life-years (QALYs) were derived by weighting survival time by estimates of health-related quality-of-life. Incremental cost-effectiveness is presented based on differences in treatments' mean costs and QALYs for the licensed population in TRITON-TIMI 38, and the sub-groups of UA-NSTEMI, STEMI, diabetes, and the 'core clinical cohort' (
AB - Objective: To evaluate the long-term cost-effectiveness of 12-months treatment with prasugrel vs clopidogrel from four European healthcare systems' perspectives (Germany, Sweden, the Netherlands, and Turkey). Methods: In the TRITON-TIMI 38 trial, patients with an acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) were treated with prasugrel or clopidogrel. Prasugrel reduced the composite end-point (cardiovascular death, MI, or stroke), but increased TIMI major bleeding. A Markov model was constructed to facilitate a lifetime horizon for the analysis. A series of risk equations constructed using individual patient data from TRITON-TIMI 38 was used to estimate risks of clinical events. Quality-adjusted life-years (QALYs) were derived by weighting survival time by estimates of health-related quality-of-life. Incremental cost-effectiveness is presented based on differences in treatments' mean costs and QALYs for the licensed population in TRITON-TIMI 38, and the sub-groups of UA-NSTEMI, STEMI, diabetes, and the 'core clinical cohort' (
UR - http://www.scopus.com/inward/record.url?scp=84875723365&partnerID=8YFLogxK
U2 - 10.3111/13696998.2013.768998
DO - 10.3111/13696998.2013.768998
M3 - Article
AN - SCOPUS:84875723365
SN - 1369-6998
VL - 16
SP - 510
EP - 521
JO - Journal of Medical Economics
JF - Journal of Medical Economics
IS - 4
ER -